First-into-human Study of NS-136 in Healthy Subjects

NCT ID: NCT06345703

Last Updated: 2024-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-30

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are:

* Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen?
* What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

The trial consists of three parts: the first part is a single ascending dose (SAD) study, the second part is a multiple ascending dose (MAD) study, and the third part is food effect (FE) study. The first two parts (SAD and MAD) will be randomized, double-blind, single or multiple ascending dose and placebo-controlled study designs. The third part (FE) will be a randomized, open-label, two-period, crossover study design. To evaluate the safety, tolerability, pharmacokinetic profile, and the effect of food on the PK profile of NS-136 in healthy subjects and to determine the maximum tolerated dose (MTD)
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm1

NS-136 SAD Dose 1

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm2

NS-136 SAD Dose 2

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm3

NS-136 SAD Dose 3

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm4

NS-136 SAD Dose 4

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm5

Arm5 NS-136 MAD Dose 1

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm6

Arm5 NS-136 MAD Dose 2

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm7

FE Grp A

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm8

FE Grp B

Group Type EXPERIMENTAL

NS-136 tablet

Intervention Type DRUG

Investigational product NS-136

Arm9

NS-136 SAD Dose 1 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Arm10

NS-136 SAD Dose 2 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Arm11

NS-136 SAD Dose 3 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Arm12

NS-136 SAD Dose 4 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Arm13

NS-136 MAD Dose 1 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Arm14

NS-136 MAD Dose 2 PBO

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

NS-136 matching placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

NS-136 matching placebo

Intervention Type DRUG

NS-136 tablet

Investigational product NS-136

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Study subjects must meet all of the following criteria for study entry:

1. Healthy males or females aged 18-65 years (inclusive), with a body mass index (BMI) between 18.00 and 32.00 kg/m2(inclusive);
2. Not participated in any other clinical trials within the past 30 days or 5 half-lives of other investigational drugs prior to the screening, whichever is longer;
3. For women of reproductive potential, a negative pregnancy test is required, and they must agree to use contraception (more details see Appendix 1) from the time of signing the informed consent form until at least 90 days after the last dose of investigational product. Male subjects must agree to use adequate contraception from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and donation of sperm or ova is prohibited during the entire study period;
4. In good health, determined by the investigator on the basis of medical history, physical examinations, vital signs, 12-lead electrocardiograms (12-ECGs), clinical laboratory tests (haematology, urinalysis, blood chemistry). Repeated examination is allowed once at investigator's discretion;
5. Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Subject voluntarily participates and signs the informed consent form before any study procedures begin.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from study entry:

1. Individuals who are allergic to the investigational product or any of its components, or who are easily allergic at investigator's discretion;
2. Individuals who are intolerant to venipuncture/venous catheterization or blood fainting or needle phobia;
3. Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), human immunodeficiency virus antibody (Anti-HIV) during the screening period;
4. Average daily smoking of more than 5 cigarettes in the 3 months prior to screening, or inability to stop using any tobacco products (including nicotine products) during the trial;
5. Excessive alcohol consumption or weekly alcohol intake exceeding 14 units of alcohol in the 4 weeks prior to screening (1 unit equals 10 grams of pure alcohol, alcohol content of different alcoholic beverages is indicated by volume ratio, approximately 1 alcohol unit is equal to 35 mL of 50° liquor or 350 mL of 5° beer), or unwillingness to stop drinking alcohol or consuming any products containing alcohol during the trial, or positive alcohol test upon screening and admission (repeated test is allowed once at investigator's discretion);
6. Excessive intake of tea, coffee, or caffeinated beverages (more than 8 cups/day, 1 cup = 250 mL) in the 3 months prior to screening, or inability to stop consuming any beverages or foods containing caffeine, any beverages or foods rich in purines, or grapefruit and other substances that may affect drug absorption, distribution, metabolism, or excretion during the trial;
7. History of drug abuse within the past year prior to the first dose, or positive results in a multi-drug urine screening test upon screening period and admission. Repeated test is allowed once at investigator discretion;
8. History of definite neurological or psychiatric disorders (including epilepsy, migraines, dementia, depression or bipolar disorder, schizophrenia, etc.); history of prolonged QTc interval; immunodeficiency or immunosuppressive diseases, malignant neoplastic diseases; chronic cardiovascular, hepatic, renal, endocrine, respiratory, hematological (including coagulation), digestive system diseases, cholecystectomy, Gilbert's Syndrome or resolved childhood asthma;
9. Underwent major surgery within the past 6 months prior to the first dose (such as coronary artery bypass grafting, hepatectomy, gynecological surgery, etc.); occurrence of acute neurological, digestive, respiratory, circulatory, endocrine, hematological, or other systemic diseases that may affect the absorption, distribution, metabolism, excretion, and safety evaluation of the investigational product within 3 months prior to screening judged by investigator;
10. Donated blood or experienced blood loss ≥400 mL within the 3 months prior to the first dose; difficulties in venous blood collection; planned blood donation during the study or within 1 month after the study;
11. Use of strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 14 days prior to the administration of the investigational drug or anticipated use of strong CYP3A4 inhibitors or inducers during the study participation period;
12. Use of any prescription or non-prescription medications, including herbal and OTC medications within 14 days of dosing, with the exception of paracetamol (≤2 g per day);
13. Receipt of vaccines within the 4 weeks prior to the first dose of the investigational product;
14. Cannot tolerate high-fat meals or have special dietary requirements, or cannot adhere to a standardized diet (only for subjects in the FE trial);
15. Other factors deemed unsuitable for participation in the trial by the investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NeuShen Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emir Redzepagic, MD

Role: PRINCIPAL_INVESTIGATOR

CMAX Clinical Research Pty Ltd

Xiaolan Yong Chief Pharmacist, BS

Role: PRINCIPAL_INVESTIGATOR

Chengdu Xinhua Hospital, China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Site Status RECRUITING

Chengdu Xinhua Hospital

Chengdu, Sichuan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Australia China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao Zhang, PhD

Role: CONTACT

8613918282581

Yangyi Qu, MS

Role: CONTACT

8613262952232

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Services Director

Role: primary

+61 08 7088 7900

Study Director

Role: primary

86-02860212019

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTR20244269

Identifier Type: OTHER

Identifier Source: secondary_id

NS136HV101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

First-in-human Study in Healthy Subjects
NCT03315338 COMPLETED PHASE1
Effects of CS-8080 in Healthy Volunteers
NCT00613431 COMPLETED PHASE1
A Phase 1 Study of S-1117
NCT06828393 RECRUITING PHASE1
Phase 1a Study in Healthy Participants
NCT05953506 UNKNOWN PHASE1
A Study of NPC-22 in Healthy Adult Males
NCT04203862 COMPLETED PHASE1
A Phase I Study to Evaluate LIFE-001
NCT06904807 RECRUITING PHASE1